


REVIEW

Open Access



# The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications

Chen-Ting Hung<sup>1†</sup>, Yi-Wei Tsai<sup>1†</sup>, Yu-Shuo Wu<sup>1†</sup>, Chih-Fan Yeh<sup>2</sup> and Kai-Chien Yang<sup>1,2,3,4,5,6\*</sup> 

## Abstract

Fibrosis-related disorders account for an enormous burden of disease-associated morbidity and mortality world-wide. Fibrosis is defined by excessive extracellular matrix deposition at fibrotic foci in the organ tissue following injury, resulting in abnormal architecture, impaired function and ultimately, organ failure. To date, there lacks effective pharmacological therapy to target fibrosis per se, highlighting the urgent need to identify novel drug targets against organ fibrosis. Recently, we have discovered the critical role of a fibroblasts-enriched endoplasmic reticulum protein disulfide isomerase (PDI), thioredoxin domain containing 5 (TXNDC5), in cardiac, pulmonary, renal and liver fibrosis, showing TXNDC5 is required for the activation of fibrogenic transforming growth factor- $\beta$  signaling cascades depending on its catalytic activity as a PDI. Moreover, deletion of TXNDC5 in fibroblasts ameliorates organ fibrosis and preserves organ function by inhibiting myofibroblasts activation, proliferation and extracellular matrix production. In this review, we detailed the molecular and cellular mechanisms by which TXNDC5 promotes fibrogenesis in various tissue types and summarized potential therapeutic strategies targeting TXNDC5 to treat organ fibrosis.

**Keywords:** Organ fibrosis, TXNDC5, Protein disulfide isomerase, Thioredoxin domain, Transforming growth factor- $\beta$  (TGF $\beta$ )

## Introduction

Fibrosis, a non-physiological repair process in multiple organs, occurs in response to chemical, immunological and physical insults, evolutionarily designed as the body's matrix synthetic machinery to repair and maintain tissue homeostasis. Upon injury, the release of multiple pro-fibrotic cytokines (such as transforming growth factor- $\beta$

[TGF $\beta$ ] and tumor necrosis factor- $\alpha$  [TNF $\alpha$ ]), growth factors (such as connective tissue growth factor [CTGF], fibroblast growth factor 2 [FGF-2], insulin-like growth factor [IGF], platelet-derived growth factor [PDGF]) and reactive oxidants from damaged cells or infiltrating inflammatory cells triggers the activation and proliferation of fibroblasts [1–3]. Activated fibroblasts transition into  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA)-expressing myofibroblasts, which are responsible for producing extracellular matrix (ECM) proteins that are required for acute tissue repair and wound healing [4]. This process is reversible once the tissue repair is completed, and activated fibroblasts are removed owing to apoptosis. If the injury to the tissue is perpetual, however, fibroblast activation becomes uncontrolled, turning themselves into

<sup>†</sup>Chen-Ting Hung, Yi-Wei Tsai and Yu-Shuo Wu contributed equally to this work

\*Correspondence: kcyang@ntu.edu.tw

<sup>1</sup> Department and Graduate Institute of Pharmacology, National Taiwan University College of Medicine, No. 1, Sec. 1, Ren-Ai Rd, 1150R, Taipei 100, Taiwan

Full list of author information is available at the end of the article



apoptosis-resistant fibrosis-associated fibroblasts (FAFs). Incessant and excessive accumulation of FAFs and ECM proteins, therefore, leads to scar formation, architectural distortion, progressive loss of tissue function and ultimately organ failure.

TGF $\beta$  is the pivotal factor that drives organ fibrosis. Although TGF $\beta$  inhibits proliferation in most cell types and triggers apoptosis in epithelial cells, it stimulates mesenchymal cell proliferation and ECM production. TGF $\beta$  is secreted as part of a large latent complex, consisting of latent TGF $\beta$ -binding protein (LTBP), latency-associated peptide (LAP) and TGF $\beta$  itself [5]. After cleavage of LTBP and LAP by matrix metalloproteases or integrins, activated TGF $\beta$  dimer is released from the complex and interacts with TGF $\beta$  receptor 2 (TGFB2) [6]. After binding with TGF $\beta$ , TGFB2 recruits and phosphorylates TGF $\beta$  receptor 1 (TGFB1), which further phosphorylates and activates SMAD2/3 to associate with SMAD4 [7]. The SMAD2/3/4 complex then enters nucleus and works with other co-transcription factors to regulate target genes to trigger the activation and trans-differentiation of resident or immigrated fibroblasts into myofibroblasts and ECM production. These activated myofibroblasts produce ECM proteins, such as collagens (Type I, III and IV), fibronectin, elastin and proteoglycan, to restore tissue integrity and maintain tissue homeostasis [8]. If the injury is not resolved properly, fibroblasts will continue to be activated to produce and accumulate excessive amounts of ECM proteins. This will consequently lead to the formation of stiff fibrotic matrix, where matrix stiffness provides mechanical stimulus to further promote fibrotic tissue remodeling and fibrosis progression [9]. In some cases, it could result in abnormal tissue architecture, function and ultimately organ failure. In addition to the canonical SMAD signaling pathway, TGF $\beta$  also stimulates non-canonical (SMAD-independent) pathways, such as mitogen activated protein (MAP) kinases (c-Jun N-terminal kinase [JNK], extracellular-signal regulated kinase [ERK] and p38), phosphatidylinositol-3-kinase (PI3K), Rho-like GTPases and janus kinases (JAKs) to induce organ fibrosis [10].

Fibrosis-related disorders cause enormous medical burden, and up to 45% of all deaths are attributed to severe fibrosis globally. However, current treatments for fibrosis have limited efficacy [11]. Of note, inhibiting the TGF $\beta$  signaling pathway directly to reduce organ fibrosis may cause undesired side effects. For example, blockage of TGF $\beta$ -mediated SMAD3 phosphorylation prevented bleomycin (BLM)-induced pulmonary fibrosis (PF); however, TGF $\beta$  or SMAD3 deletion caused abnormal lung organogenesis and systemic inflammation in mouse models [12, 13]. These evidence suggest that inhibition of TGF $\beta$  may cause systematic adverse effects and may not

be an ideal therapeutic target for organ fibrosis. Delineating and leveraging novel mechanisms underlying organ fibrogenesis to develop potential therapeutic approaches, hence, are urgently needed [14]. Here, we discuss the current knowledge on the novel role of an endoplasmic reticulum (ER) protein thioredoxin (TRX) domain containing 5 (TXNDC5) in the pathogenesis of fibrosis, the underlying molecular/cellular mechanisms and the potential approaches to treat organ fibrosis by targeting TXNDC5.


### **Thioredoxin domain containing 5 (TXNDC5)**

TXNDC5, also known as endothelial protein disulfide isomerase (Endo-PDI), endoplasmic reticulum protein 46 (ERp46) or protein disulfide isomerase family A, member 15 (PDI15), is a member of PDI family. TXNDC5 catalyzes the formation of native disulfide bonds and rearranges the disulfide bonds via its TRX domains in the ER [15, 16]. Each TRX domain harbors a CGHC motif that serves as the catalytic domain for PDI activity (Fig. 1). Functionally, TXNDC5 facilitates proper protein folding, prevents unfolded protein response (UPR)-related apoptosis [15, 17], and mediates redox reaction via interacting with NADPH oxidase [18]. Moreover, TXNDC5 synergizes with heat shock cognate 70 protein (HSC70), another chaperone protein, to exacerbate the inflammatory phenotypes through NF- $\kappa$ B signaling, independent of its PDI activity [15, 19].

TXNDC5 was found enriched in endothelial cells (ECs) and fibroblasts [20], where TXNDC5 dysregulation was implicated in multiple diseases, including organ fibrosis, atherosclerosis, diabetes, liver disease, rheumatoid arthritis (RA), cancer, neurodegenerative disease and vitiligo [15, 21, 22]. In addition, TXNDC5 expression is induced under hypoxic conditions in disease states, including RA [23], non-small cell lung cancer [24], and colorectal cancer. A previous study demonstrated that TXNDC5 renders EC resistant to hypoxia-initiated apoptosis [20]. Taken together, current evidence suggests that aberrant TXNDC5 expression could contribute to a wide spectrum of diseases through its distinct functions in different cell types.

### **The pathological role of TXNDC5 in organ fibrosis**

TXNDC5 was reported to promote fibrosis in multiple organs, including the heart [25], lung [26], kidney [27], and liver [28], as the intermediary of TGF $\beta$  signaling (scheme shown in Fig. 1). TXNDC5 promotes tissue fibrosis through activation of canonical (SMAD3-dependent) or non-canonical (MAP kinases, such as JNK, ERK and pro-survival protein STAT3) TGF $\beta$  signaling. TGF $\beta$  induces TXNDC5 upregulation via increased ER stress level and activating transcription factor 6



(ATF6)-mediated transcriptional control. In addition, TRX domains of TXNDC5 contribute to the proper folding and stabilization of pro-fibrotic proteins. This TGFβ-ATF6-TXNDC5 signaling axis highlights the crucial role of TXNDC5 in fibrogenesis, although its downstream

signaling mediators are slightly different in individual organs (shown in Table 1). In the following sections, we will describe the detailed mechanisms by which TXNDC5 mediates the development of organ fibrosis in heart, lung, kidney and liver.

**Table 1** TGFβ-ATF6-TXNDC5 signaling axis triggers various downstream fibrogenic signaling pathways in different organs

Organ fibrosis	TXNDC5 downstream signaling pathway
Cardiac fibrosis [25]	<ol style="list-style-type: none"> <li>1. Non-canonical TGFβ pathway: JNK signaling</li> <li>2. Facilitating folding of ECM protein, such as collagen and fibronectin</li> </ol>
Pulmonary fibrosis [26]	<ol style="list-style-type: none"> <li>1. Canonical TGFβ pathway: SMAD3 signaling</li> <li>2. Non-canonical TGFβ pathway: JNK and ERK signaling</li> <li>3. Post-translationally stabilizing TGFβR1 protein</li> </ol>
Renal fibrosis [27]	<ol style="list-style-type: none"> <li>1. Canonical TGFβ pathway: SMAD3 signaling</li> <li>2. Post-translationally stabilizing TGFβR1 protein</li> </ol>
Liver fibrosis [28]	<ol style="list-style-type: none"> <li>1. Non-canonical TGFβ pathway: JNK and STAT3 signaling</li> </ol>

### The role of TXNDC5 in cardiac fibrosis (CF)

Heart failure (HF) is one of the major public health problems globally, with a rising prevalence and high mortality rate [29, 30]. Although medical advances reduce the mortality rates of cardiovascular diseases (CVD), including hypertensive heart disease, acute coronary syndrome, congenital and valvular heart diseases, it remains critical to develop novel treatment strategies for HF to reduce mortality rate [31, 32]. In addition to abnormalities in cardiomyocytes, CF contributes to cardiac remodeling and plays an important role in the progression of HF [33, 34]. Replacement of cardiac muscles by fibrotic tissues reduces systolic function following cardiac injury [33, 34]. Excessive ECM accumulation causes wall stiffness and results in diastolic as well as systolic dysfunction [33–35]. In addition to cardiac function, increased production of cardiac fibrotic tissues leads to enhanced cardiac automaticity and triggered activity, which can foster life-threatening arrhythmias [36, 37]. Targeting CF, therefore, may provide a novel therapeutic venue against contractile dysfunction, arrhythmias and death in HF.

During CF progression, renin–angiotensin–aldosterone system (RAAS), endothelin-1 (ET-1) and TGF $\beta$ 1 expression levels are increased to trigger the activation and proliferation of fibroblasts [1–3]. Activated cardiac fibroblasts transdifferentiate into  $\alpha$ -SMA-expressing myofibroblasts, secreting fibrillar collagen and multiple ECM proteins at the fibrotic foci [4]. Myofibroblasts also modulate ECM turnover through matrix metalloproteinases (MMPs) and tissue inhibitor of MMPs (TIMPs) to promote ECM accumulation during CF progression [38].

To date, therapeutic strategies against CF remain suboptimal. Using inhibitors targeting RAAS, including angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and mineralocorticoid receptor antagonist, has shown benefits in improving ventricular function and slow CF progression [39–41]. Nevertheless, these treatments cause a hypotensive effect which limited their capability to slow CF progression. Meanwhile, treatment using non-selective TGF $\beta$  inhibitors reduces fibrosis progression by attenuating fibroblast activation and ECM deposition in animal models [42–44]. However, these non-selective TGF $\beta$  inhibitors cause undesired side effects such as liver toxicity, limiting their clinical application [45]. Besides RAAS and TGF $\beta$ , therapeutic strategies targeting other fibrogenic molecules such as TGF $\beta$  activated kinase 1, p38, endothelin receptors, G protein-coupled receptor kinase 2 and miR21 have been investigated in preclinical studies [25, 46–50].

Recently, PDI family proteins have been implicated in multiple CVD [51]. Multiple studies have delineated the mechanisms by which PDIs contribute to the pathogenesis of CVD and shown the feasibility to treat these

conditions by targeting PDIs [25, 52, 53]. Recently, Shih et al. reported that TXNDC5, or PDI15, regulates ECM accumulation and fibrosis progression [25]. TXNDC5 expression is upregulated in cardiac fibroblasts in human and mouse failing hearts with pathological cardiac hypertrophy. TXNDC5, a resident protein in the ER, facilitates ECM protein folding and activates cardiac fibroblasts via redox-sensitive JNK signaling pathway through its PDI activity. Deletion of TXNDC5 protects against isoproterenol-induced myocardial fibrosis, hypertrophy and contractile dysfunction in mice [25]. Because upregulation of TXNDC5 expression is restricted in activated cardiac fibroblasts, targeting TXNDC5, therefore, could inhibit CF with fewer undesired side effects than targeting TGF $\beta$  and RAAS.

### The role of TXNDC5 in pulmonary fibrosis (PF)

PF is a progressive clinical condition in which excessive buildup of fibrotic or scarring in the lung leads to the distorted pulmonary/alveolar structure, impaired lung function and gas exchange. Consequently, PF results in dyspnea, hypoxemia, exercise intolerance and ultimately death. Idiopathic PF (IPF), characterized by varying degrees of inflammation and scarring in the lung, is the most common type of interstitial lung diseases of unknown etiology. In Asia–Pacific countries, the adjusted incidence and prevalence of IPF ranged from 3.5 to 13 and 5.7 to 45.1 cases per 100,000 population, respectively [54]. Exploiting large population-based database of the Taiwan National Health Insurance, the accumulative prevalence rates increased steadily from 3.1 to 6.4 cases per 100,000 people per year during 2006–2011 based on a narrow case definition. More importantly, the mean survival time after IPF diagnosis is 6.9 year [55]. PF has become a huge economic and clinical burden globally. The therapeutic approaches for PF remain suboptimal to improve the quality of life and even increase survival due to insufficient understanding of pathogenetic mechanisms of PF [56]. Therefore, there is an urgent need to develop the novel therapies to improve the outcomes of PF patients.

The complex pathophysiological mechanisms including genetic predisposition and injury types may account for the initiation and progression of PF. In general, fibrosis is resulted from repetitive injury in alveolar epithelial cells by exogenous (e.g., infection, toxin and radiation) or endogenous (e.g., inflammation, oxidative stress and aberrant immune responses) stimuli. Increased profibrotic and inflammatory cytokines, including TGF $\beta$ , TNF $\alpha$ , CTGF, PDGF, etc., induce a series of signaling cascades to initiate the activation and proliferation of lung fibroblasts [57]. Activated fibroblasts are transdifferentiated into collagen-secreting myofibroblasts, which



promote the production of fibrogenic ECM proteins and cause an imbalance between MMPs and its inhibitors, TIMPs, leading to excessive ECM accumulation at fibrotic foci and resulting in abnormal lung structure [58]. In addition, ER stress increases in response to lung injury, triggering myofibroblast transdifferentiation and epithelial–mesenchymal transition, both of which can contribute to PF [59, 60].

Immunosuppressive and immunomodulatory therapies, such as a combination of prednisone, azathioprine and *N*-acetylcysteine, exhibit limited therapeutic effects in terms of mortality and hospitalization [61, 62]. In addition, targeting pro-fibrotic cytokines and chemoattractants, such as etanercept, a recombinant soluble human TNF receptor, and carlumab, a CC-chemokine ligand 2 monoclonal antibodies, also fails to improve IPF outcomes [63, 64]. Currently, two drugs, pirfenidone (5-methyl-1-phenylpyridin-2[1*H*]-one) and nintedanib, are utilized to treat IPF. Pirfenidone, a synthetic compound of phenyl pyridine, inhibits the TGF $\beta$  signaling and other inflammatory cytokines (e.g., TNF $\alpha$  and IL-1 $\beta$ ) [65, 66]. Clinical trials revealed that pirfenidone delays disease progression and prevents deterioration of pulmonary function in IPF patients [67–69]. Exploring pooled analyses and meta-analyses of clinical trials, pirfenidone was shown to provide outcome benefits [70]. Nintedanib, a tyrosine kinase inhibitor, targets vascular endothelial growth factor receptor, FGF receptor and PDGF receptor. By suppressing the kinase activities, nintedanib also slows down disease progression of IPF, although mild to moderate diarrhea and nausea are observed in most cases [71]. Collectively, both agents show the potential to attenuate PF through inhibition of inflammation. However, these two agents are not able to stop the progression of IPF and there is an urgent need to develop newer therapies to improve the outcome of IPF patients.

Recent study by Lee et al. demonstrated that TXNDC5 is involved in the progression of IPF through modulating TGF $\beta$  signaling [26]. In this study, the transcript and protein expression of TXNDC5 are upregulated in the lung tissues of human IPF patients and mice with BLM-induced lung fibrosis. Mechanistically, TGF $\beta$ 1 stimulation induces TXNDC5 upregulation in lung fibroblasts via increased ER stress levels and ATF6-mediated transcriptional regulation. Consequently, both TGF $\beta$  canonical- (SMAD3) and non-canonical (JNK and ERK) signaling are activated, resulting in the activation, transdifferentiation, proliferation and ECM production in lung fibroblasts. TXNDC5 enhances the protein stability of TGFBR1, but not TGFBR2, leading to amplification of TGF $\beta$  signaling. Importantly, forced expression of mutant TXNDC5 (Cys-to-Ala mutations at the both ends in the CGHC motif of the three TRX domains) in

lung fibroblasts inhibits PDI activity, lowers the protein expression of TGFBR1 and consequently inactivates its downstream signaling pathways. Collectively, TXNDC5 stabilizes TGFBR1 and augments TGF $\beta$  signaling, generating a positive feedback loop of TGF $\beta$ 1-ATF6-TXNDC5-TGFBR1 signaling axis to cause severe scarring in the lung [26]. In addition, global deletion of *Txndc5* protects against BLM-induced PF and impairment of pulmonary function without altering inflammatory response to BLM. Utilizing inducible fibroblast-specific deletion of *Txndc5* further confirms the pathogenic requirement of fibroblastic TXNDC5 in the development and progression of lung fibrosis, thereby preventing and even reversing pulmonary dysfunction in BLM-treated animals. Taken together, these results show that TXNDC5 modulates TGF $\beta$  signaling activity during the development of lung fibrosis and highlight the therapeutic potential to treat patients with PF by targeting TXNDC5 in lung fibroblasts.

#### The role of TXNDC5 in renal fibrosis (RF)

Chronic kidney disease (CKD) is caused by chronic and progressive injuries to kidney tissue. The rising prevalence of metabolic diseases, inflammation, hypertension and obesity, as well as aging increases the risk of kidney injury [72]. CKD affects more than 10% of the population worldwide, with an estimated prevalence of 11.7 to 15.1%. Advanced CKD can turn into end-stage renal disease (ESRD). Patients with ESRD requiring dialysis or kidney transplantation are estimated to be between 4.902 and 7.083 million, representing a substantial clinical and socioeconomic burden [73]. Moreover, Taiwan has the highest incidence of CKD (estimated prevalence of 15.46%) in Asia [74]. In order to repairing the damaged tissues by wound healing, fibrogenic proteins are produced in response to kidney injury, resulting in excessive accumulation of fibrogenic proteins at fibrotic area and consequently RF. Glomerulosclerosis and tubulointerstitial fibrosis are the most common types of fibrosis observed in CKD.

Dysregulation of RAAS plays a major pathological role in CKD-induced fibrosis [75]. Angiotensin II triggers the release of pro-fibrotic factors, leading to renal inflammation and fibrosis [76, 77]. The standard therapy to delay the progression of CKD is blockade of RAAS using ACEIs, ARBs, or direct renin blockers. Among antihypertensive agents, both ACEIs and ARBs are considered as the feasible approaches against RF, including lowering blood pressure, reducing proteinuria, ameliorating RF and delaying the progression of CKD [77–79]. RAAS blockade, however, is not sufficient to halt the progression of CKD in many cases. In addition, the endothelins, especially ET-1, promote RF through increasing renal

vasoconstriction and glomerular pressure [80]. In a pre-clinical study, ET-1 receptor A ( $ET_A$ ) antagonist, ABT-627, has shown to prevent glomerulosclerosis, attenuate vascular fibrosis and collagen deposition in hypertensive rats [81, 82]. However, two clinical trials raised the safety concerns using  $ET_A$  antagonists, including significant fluid overload and congestive HF, in patients with renal diseases [83, 84].

TGF $\beta$ , as shown in the previous sections, is known to promote fibrosis in most, if not all, organs, and thereby numerous therapeutic are designed to target TGF $\beta$  or its downstream signaling. The humanized anti-TGF $\beta$  antibody, LY2382770, is designed to neutralize TGF $\beta$ , failed to show therapeutic efficacy against CKD [85]. Pentoxifylline, a nonspecific phosphodiesterase inhibitor, attenuates tubulointerstitial fibrosis in CKD animal model (unilateral ureteral obstruction [UUO]) by interfering with the transcription of SMAD3/4 to suppresses CTGF [86]. Pentoxifylline was shown to improve renal function in high-risk patients, however, this study lacks its power due to small sample size and incomplete follow-up [87]. Directly targeting fibrogenic proteins such as CTGF is an alternative approach. Indeed, reducing CTGF expression levels by antisense oligonucleotide (ASO) significantly attenuates the progression of CKD and fibrosis in mice subjected to UUO surgery [88]. Even though intravenous administration of CTGF antibody (FG-3019) in patients with diabetic kidney disease significantly decreases albuminuria without obvious adverse effects, the safety concerns, such as the interference with CTGF-dependent skeletogenesis, still exist as CTGF is involved in more complex biological processes, such as angiogenesis, chondrogenesis and osteogenesis. [89, 90]. Finally, pirfenidone, approved by US Food and Drug Administration (FDA) to treat IPF, also exhibits anti-fibrotic effects in the RF animal models by suppressing the mesangial matrix expansion [91]. However, the therapeutic effects of pirfenidone in RF patients are inconsistent, requiring more clinical trials to prove its efficacy [92, 93].

A recent study by Chen et al. [27] demonstrated that TXNDC5 modulates TGF $\beta$ /ATF6/TGF $\beta$ R1 signaling axis in RF, similar to that observed in PF [26]. The transcript and protein expressions of TXNDC5 are upregulated in the kidneys of CKD patients and mice, especially in collagen-secreting kidney fibroblasts. The ATF6-dependent ER stress pathway transcriptionally regulates TXNDC5 in fibroblasts following TGF $\beta$  stimulation. Depletion of TXNDC5 attenuates in human kidney fibroblasts activation, proliferation and ECM production induced by TGF $\beta$ 1. Forced TXNDC5 expression not only triggers human kidney fibroblasts activation, proliferation and ECM production but also augments TGF $\beta$ R1 protein stabilization to activate TGF $\beta$  canonical signaling pathway,

resulting in a “positive feedback loop”. However, such phenotypes are abolished in overexpressing catalytically dead TXNDC5 with mutant TRX domains. In addition, targeting TXNDC5 in kidney fibroblast attenuates the extent of scarring in multiple RF mouse models, including UUO, unilateral ischemia–reperfusion injury and folic acid-induced RF. Deletion of *TxnDC5* in other kidney cell types, including renal tubular epithelial cells, podocytes and ECs, however, has no obvious impact on fibrosis progression. More importantly, inducing deletion of *TxnDC5* in kidney fibroblasts in animals with existing UUO-induced RF completely halted the progression of fibrosis and preserves kidney function. Taken together, these results illustrate that targeting TXNDC5 in renal fibroblasts attenuates the progression of RF by breaking down the positive feedback loop of TGF $\beta$ /ATF6/TGF $\beta$ R1 signaling axis.

#### The role of TXNDC5 in liver fibrosis (LF)

LF is caused by chronic liver injuries [94], including viral infection, alcohol use, non-alcoholic steatohepatitis (NASH) and obstructive biliary diseases including primary biliary cholangitis, primary sclerosing cholangitis and biliary atresia [95, 96]. Chronic hepatocellular injury leads to damage of epithelial/endothelial barrier, release of inflammatory cytokines and recruitment of inflammatory cells, followed by the secretion of pro-fibrotic cytokines. Hepatic myofibroblasts are then activated to produce excessive ECM proteins for the formation of fibrous septae and regeneration nodules [96, 97]. Myofibroblasts originate from hepatic resident cells, including hepatic stellate cells (HSCs) and portal fibroblasts, or bone marrow-derived cells, including fibrocytes and mesenchymal stem cells [98–101]. Although multiple cell types contribute to ECM production, HSC is a major source of ECM and contributes to the pathogenesis of almost all types of LF [102].

In normal liver, quiescent HSCs reside in the space of Disse between hepatocytes and liver sinusoidal endothelial cells, function as pericytes and are the major storage sites of vitamin A [103–105]. These HSCs contribute to one-third of non-parenchymal cells in the liver and exhibit a non-proliferative, quiescent phenotype in normal liver [103, 106, 107]. In response to liver injury, damaged hepatocytes and inflammatory cells secrete fibrogenic cytokines, including TGF $\beta$ , TNF $\alpha$ , CTGF, etc., and reactive oxidants, which activate and transform quiescent HSCs into highly proliferative myofibroblasts [103].

LF can be reversible if the underlying causes of liver injury are removed in its early stages [108]. For example, antiviral therapy is associated with reduced Child–Pugh scores in viral hepatitis caused by hepatitis B virus or

hepatitis C virus [109, 110]. Abstinence from alcohol also shows great efficacy of restoring liver function in alcohol-related liver disease [111]. For NASH induced by overweight and obesity, reducing body weight through dietary and lifestyle modification is effective to treat NASH [112–114]. If liver damage reaches irreversible stages and end-stage cirrhosis ensues, liver transplantation remains the only curative treatment. To date, therapies directly targeting LF remain unavailable. Importantly, therapies targeting underlying sources of liver injury, such as antiviral therapy against hepatitis B virus infection, are expensive and may require lifelong medication. Moreover, there is no approved medication for NASH so far [108, 113]. Therefore, therapies to reduce HSC activation and ECM accumulation directly emerge as a new approach to treat LF and liver cirrhosis.

The role of ER protein TXNDC5 has been recently studied in the progression of LF [28]. Hung et al. demonstrated TXNDC5 is considerably expressed in activated HSCs and at fibrotic foci of the livers from human patients and mice with liver fibrosis/cirrhosis. TXNDC5 induces HSC activation through reactive oxygen species (ROS)-dependent JNK signaling; TXNDC5 also renders HSCs resistant to apoptosis via STAT3 signaling, leading to accumulation of activated HSCs and excessive fibrotic scar in the liver. Inhibiting the catalytic function of TXNDC5 abolishes JNK and STAT3 activation and the downstream fibrotic responses. Intriguingly, targeted ablation of *TxnDC5* in HSCs, but not hepatocytes, significantly protects against the development and progression of LF in mice with hepatotoxic ( $\text{CCl}_4$  treatment) or cholestatic (bile duct ligation) injury, as evidenced by a lower fibrillar collagen deposition and preservation of liver function. Taken together, targeting TXNDC5 may build a new avenue for liver fibrosis/cirrhosis treatments via blocking HSC activation, proliferation, ECM production, as well as depriving anti-apoptotic capacity of HSCs.

Upon acute or chronic liver injury, pro-fibrotic cytokine TGF $\beta$  triggers activation of ER stress pathway. ATF6-p50, an active form of ATF6, translocates into the nucleus from the cytoplasm to physically interact with the promoter of TXNDC5, leading to TXNDC5 upregulation. Increased TXNDC5 expression leads to transdifferentiation of HSCs into myofibroblasts, resulting in considerable myofibroblast proliferation and ECM production. These responses depend on the redox-activity of TXNDC5 to trigger TGF $\beta$  canonical and non-canonical signaling and stabilize ECM and TGF $\beta$ R1 proteins, leading to a positive feedback loop of TGF $\beta$ /ATF6/TGF $\beta$ R1 signaling.

Taken together, these studies suggest that TXNDC5 is a critical yet previously unrecognized mediator of organ fibrosis. TXNDC5 mediates organ fibrosis through 4

distinct, context-dependent mechanisms: (1) facilitating ECM protein folding, including collagen and fibronectin; (2) stabilizing TGF $\beta$ R1 protein; (3) triggering TGF $\beta$  non-canonical JNK signaling to induce fibroblast activation and proliferation; (4) activating phosphorylated STAT3 to render fibroblasts resistant to apoptosis. Figure 2 summarizes the detailed mechanisms by which TXNDC5 promotes organ fibrosis.


### The role of TXNDC5 in other fibrosis-related diseases

Because fibroblasts are a major cellular constituent in almost all tissues, fibrosis can be involved in the dysfunction of multiple organs. RA, for example, is a chronic inflammatory disease characterized by hyperplasia of synovial fibroblasts, causing progressive joint destruction, chronic synovitis and consequently functional disability [115]. Clinical studies indicated that treatment begins early with medications that remises symptoms. In general, medications for RA includes anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, and relieves symptoms drugs, such as methotrexate, leflunomide, hydroxychloroquine, etc. Previously, Wang et al. reported that TXNDC5 is detected in synovial tissues and blood from RA patients [116]. Increased TXNDC5 results in abnormal proliferation and migration of synovial fibroblasts, which are detected in the joints of the toe, knee and the ankle, in TXNDC5 transgenic mice following collagen-induced arthritis. Moreover, hypoxia induces synovial fibroblasts proliferation, migration and TXNDC5 expression, whereas reducing TXNDC5 inhibits these responses. Additionally, TXNDC5 has been reported to synergize with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts via activating NF- $\kappa$ B signaling by destabilizing I $\kappa$ B $\beta$  protein [19]. Collectively, targeting TXNDC5 might be a potential therapy to reduce joint destruction and synovitis in RA patients.

### Therapy approaches and clinical applications to target TXNDC5

Currently, pirfenidone, is the only anti-fibrotic agent approved by FDA for treating IPF via, at least partially, suppressing TGF $\beta$  signaling [117]. However, TGF $\beta$  is an important growth factor that controls many cellular responses, including proliferation, differentiation, etc., and implicates in the development and homeostasis of most human tissues. Therefore, inhibition of TGF $\beta$  could result in unexpected and harmful side effects. Leveraging the abovementioned pathological mechanism, targeting ER stress and PDI, particularly TXNDC5, offers a new way to design anti-fibrotic drugs. We will discuss some





**Fig. 2** Summary of the molecular mechanisms by which TXNDC5 promotes organ fibrogenesis. Schematic illustration of the mechanisms by which TXNDC5 contributes to organ fibrosis. TGFβ-stimulated ER stress activates the ATF6 branch, which transcriptionally activates TXNDC5 by physically interacting with TXNDC5 promoter. Increased TXNDC5 levels promote fibrogenic responses through 4 context-dependent mechanisms including (1) facilitating proper folding of fibrogenic ECM proteins, (2) stabilizing TGFβ receptor 1, and activating TGFβ non-canonical (3) JNK and (4) STAT3 signaling

potential strategies to target TXNDC5 as the treatment of organ fibrosis.

**Inhibition of ER stress response to repress TXNDC5 expression**

4-Phenylbutyric acid (4-PBA) is an US FDA-approved drug and currently used for the treatment of urea cycle disorders. 4-PBA is metabolized through β-oxidation to phenylacetate and then conjugated to glutamine to form phenylacetylglutamine, which is excreted by the kidneys [118, 119]. Mechanistically, it inhibits the aggregation of misfolded proteins and mitigates ER stress, suggesting

its potential to treat fibrosis [120]. Indeed, recent studies demonstrated that treatment with 4-PBA significantly downregulates fibrosis-related genes (TGFβ1, phospho-SMAD2 and pro-collagen isoform) induced by pressure overload, prevents the activation of UPR and decreases collagen deposition, halting the development of CF and adverse remodeling [121, 122]. Additionally, blocking ER stress by 4-PBA treatment successfully attenuates UUU-induced kidney fibrosis in rats, as reflected by the lower expression of pro-fibrotic proteins (collagen type 1α, fibronectin and α-SMA) [123]. In addition to the evidence mentioned above, pre-treatment with 4-PBA



reduces TGF $\beta$ -induced TXNDC5 expression in the human fibroblasts from multiple organs, including the heart, lung, kidney, and liver, suggesting its potential use to repress TXNDC5 expression caused by TGF $\beta$ -induced ER stress, thereby attenuating organ fibrosis [25–28].

Tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, is one of the chemical chaperons and is approved by FDA for use in biliary cirrhosis and cholestatic liver diseases based on its choleric effects [124]. Recent studies have demonstrated that TUDCA might be therapeutic in several diseases, including neurodegenerative diseases, osteoarthritis, vascular diseases and diabetes [125–128]. Functionally, TUDCA ameliorates ER stress and prevents UPR dysfunction in part by improving protein folding capacity and by supporting the transfer of mutant proteins [129]. A previous study revealed that TUDCA serves as an inhibitor of apoptosis by negatively regulating the mitochondrial pathway of cell death, reducing ROS production and inhibiting apoptosis associated with ER stress [130]. In addition, treatment with TUDCA, in human cardiac fibroblasts, leads to a reduction of TGF $\beta$ -induced TXNDC5 expression via blocking ER stress, thereby attenuating cardiac fibrogenesis in mice [25].

Collectively, blocking ER stress could be an effective strategy to inhibit TXNDC5 expression in fibroblasts, thereby inhibiting fibrogenesis. However, upregulation of ER stress and UPR activation enhances not only the capacity of protein folding and maturation but also protein degradation and transport pathway, thereby alleviating the burden of misfolded protein [131]. Therefore, overt suppression of ER stress may result in an imbalance of homeostasis, and consequently causing undesired side effects.

#### Functional inhibition of TRX domains of TXNDC5

The PDI-activity mediated by the TRX domains is essential for TXNDC5 to trigger ROS production and stabilizing fibrogenic proteins. Therefore, therapeutic agents that target TRX domains can inhibit PDI activity of TXNDC5, leading to attenuated fibrogenic responses. An irreversible PDI activity inhibitor, 16F16, covalently binds to the active site of cysteines and has been shown to prevent oxidation of the targeted protein, suppress misfolded proteins-induced apoptosis and protect against neurodegenerative disorders caused by accumulation of misfolded proteins [132, 133]. In addition, 16F16 inhibits functional activity of TXNDC5 via blocking TRX domains, leading to inhibition of redox-sensitive pro-fibrotic signaling pathways of TXNDC5 [25, 28]. However, 16F16 is a non-selective PDI inhibitor because it also targets TRX domains in other PDI family proteins. Some PDIs are known to

be essential for normal physiological functions, such as regulation of calcium release in muscle [134], and the development of the mucus-secreting cement gland [135]. Developing a TXNDC5-specific PDI inhibitor could be a powerful way to treat fibrosis without the risk of disturbing the homeostasis in non-fibroblast cells and other organ functions.

#### Targeted deletion of TXNDC5 by genetic targeting therapies

Although the aforementioned in vitro and in vivo evidence have shown targeting TXNDC5 in mouse fibroblasts successfully halts the progression of fibrosis in multiple organs, it remains challenging to design applicable therapeutic strategies to specifically target TXNDC5 in human fibroblasts. Numerous genetic targeting therapies, including small interfering RNA (siRNA), inhibitory ASO, etc., have currently charted into clinical trials and been approved to treat diseases [136]. For example, the first FDA-approved double-stranded siRNA therapeutics, patisiran (ONPATRO™), encapsulated in lipid nanoparticles for delivery to hepatocyte, is used to treat the polyneuropathy of hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) in adults [137]. In addition, Inotersen, an ASO inhibitor of the hepatic production of transthyretin protein, is also approved by FDA to treat hATTR [138]. Designing TXNDC5-targeting siRNA or specific ASO to target its TRX domain could be useful to treat fibrotic diseases by repressing TXNDC5 expression and interfering with its PDI activity.

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated 9 protein (CRISPR/Cas9) system is a revolutionary gene-editing technology and has been extensively exploited in biomedical research and clinical investigation [139, 140]. CRISPR/Cas9 complex comprised by a single guide RNA and Cas9 protein, leading to double-stranded breaks at anchored site of the target gene. Yeh et al. has recently utilized nanoparticles carrying an endothelium-specific *TxnDC5*-targeting CRISPR/Cas9 vectors to specifically delete endothelial TXNDC5, which effectively ameliorates disturbed blood flow-induced carotid atherosclerosis [22]. CRISPR/Cas9 therapy had also been approved by FDA to treat certain genetic diseases in human patients, such as correcting the mutation of a  $\beta$ -globin gene in the sickle cell disease [141].

Taken together, therapeutic strategies using RNAi, ASO and CRISPR/Cas9 system encapsulated by nanoparticles to delete fibroblast-specific TXNDC5 could be a potential therapeutic approach against organ fibrosis in the future.

## Conclusions

Emerging evidence has demonstrated the essential role of TXNDC5 in organ fibrogenesis by inducing fibroblast activation, proliferation and ECM production through its PDI activity. TXNDC5 forms a complex regulatory network to amplify TGF $\beta$ -induced fibrogenic response via folding/stabilizing ECM and TGF $\beta$ R1 proteins. More importantly, therapeutic strategies to target TXNDC5 have unique advantages due to its fibroblast-restricted expression pattern and the fact that it's non-essential for physiological function. Therefore, novel small molecules, gene-editing approaches, siRNA or ASO that target TXNDC5 could be a powerful approach to treat or prevent organ fibrosis and preserve organ function.

## Abbreviations

4-PBA: 4-Phenylbutyric acid; ATF6: Activating transcription factor 6; ACEI: Angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; ASO: Antisense oligonucleotide; BLM: Bleomycin; CF: Cardiac fibrosis; CKD: Chronic kidney disease; JNK: c-Jun N-terminal kinase; CRISPR: Clustered regularly interspaced short palindromic repeats; CTGF: Connective tissue growth factor; CRISPR/Cas9: CRISPR-associated 9 protein; ER: Endoplasmic reticulum; ERp46: Endoplasmic reticulum protein 46; ECs: Endothelial cell; Endo-PDI: Endothelial protein disulfide isomerase; ET-1: Endothelin-1; ETA: Endothelin-1 receptor a; ESRD: End-stage renal disease; ECM: Extracellular matrix; ERK: Extracellular-signal regulated kinase; FGF-2: Fibroblast growth factor 2; FAFs: Fibrosis-associated fibroblasts; FDA: Food and Drug Administration; HSC70: Heat shock cognate 70 protein; HSCs: Hepatic stellate cells; IPF: Idiopathic pulmonary fibrosis; IGF: Insulin-like growth factor; JAKs: Janus kinases; LAP: Latency-associated peptide; LTBP: Latent TGF $\beta$ -binding protein; LF: Liver fibrosis; MMPs: Matrix metalloproteinases; MRA: Mineralocorticoid receptor antagonist; MAP: Mitogen activated protein; NSAIDs: Nonsteroidal anti-inflammatory drugs; PI3K: Phosphatidylinositol-3-kinase; PDGF: Platelet-derived growth factor; PDI: Protein disulfide isomerase; PDI15: Protein disulfide isomerase family a, member 15; PF: Pulmonary fibrosis; ROS: Reactive oxygen species; RF: Renal fibrosis; RAAS: Renin-angiotensin-aldosterone system; siRNA: Small interfering RNA; TUDCA: Tauroursodeoxycholic acid; TGF $\beta$ : Transforming growth factor- $\beta$ ; TGFBR1: TGF $\beta$  receptor 1; TGFBR2: TGF $\beta$  receptor 2; TRX: Thioredoxin; TXNDC5: Thioredoxin domain containing 5; TIMPs: Tissue inhibitor of MMPs; TTR: Treat the polyneuropathy of hereditary transthyretin; hATTR: Treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis; TNF $\alpha$ : Tumor necrosis factor- $\alpha$ ; UPR: Unfolded protein response; UUU: Unilateral ureteral obstruction;  $\alpha$ -SMA:  $\alpha$ -Smooth muscle actin.

## Acknowledgements

None.

## Author contributions

CTH, YWT, YSW, CFY and KYC drafted, and revised the manuscript. All authors read and approved the final manuscript.

## Funding

This work was funded by Taiwan Ministry of Science and Technology Grants 108-2314-B-002-199-MY3, 109-2628-B-002-032, 110-2628-B-002-054 and 111-2314-B-002-069-MY3 (KCY); an Innovative Research Grant from Taiwan National Health Research Institute NHRI-EX109-10936SI (KCY), a CRC Translational Research Grant IBMS-CRC111-P01 (KCY), a Translational Medicine Grant AS-TM-109-01-04 (KCY) and a Grand Challenge Grant AS-GC-110-05 from Academia Sinica, Taiwan; grants from National Taiwan University Hospital NTUH. VN110-01, VN111-08, 109-EDN05, 110-EDN02, 109F005-110-B3, 109-S4576, 110-S4836, 111-S-0042, 110-T16, 109F005-110-B2, 111-IF0005 (KCY), grants from the Excellent Translation Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University Hospital, NSCC-MOH-131-41, 109C101-41, 110C101-071(KCY) and Career Development Grants from National Taiwan University 109L7872, 109L7753, 110L7753 (KCY).

## Availability of data and materials

Not applicable.

## Declarations

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare no competing interests.

## Author details

<sup>1</sup>Department and Graduate Institute of Pharmacology, National Taiwan University College of Medicine, No. 1, Sec. 1, Ren-Ai Rd, 1150R, Taipei 100, Taiwan. <sup>2</sup>Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan. <sup>3</sup>Research Center for Developmental Biology & Regenerative Medicine, National Taiwan University, Taipei, Taiwan. <sup>4</sup>Center for Frontier Medicine, National Taiwan University Hospital, Taipei, Taiwan. <sup>5</sup>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. <sup>6</sup>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Received: 2 July 2022 Accepted: 25 August 2022

Published online: 02 September 2022

## References

1. Fredj S, Bescond J, Louault C, Potreau D. Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. *J Cell Physiol*. 2005;202(3):891–9.
2. Lucas JA, Zhang Y, Li P, Gong K, Miller AP, Hassan E, et al. Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. *Am J Physiol Heart Circ Physiol*. 2010;298(2):H424–32.
3. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. *J Clin Investig*. 2007;117(3):568–75.
4. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. *J Pathol*. 2003;200(4):500–3.
5. Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K, Rifkin DB. Latent TGF-beta-binding proteins. *Matrix Biol*. 2015;47:44–53.
6. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. *Respir Res*. 2016;17:23.
7. Budi EH, Duan D, Derynck R. Transforming growth factor-beta receptors and smads: regulatory complexity and functional versatility. *Trends Cell Biol*. 2017;27(9):658–72.
8. Ghosh AK, Quaggin SE, Vaughan DE. Molecular basis of organ fibrosis: potential therapeutic approaches. *Exp Biol Med (Maywood)*. 2013;238(5):461–81.
9. Froese AR, Shimbori C, Bellaye PS, Inman M, Obex S, Fatima S, et al. Stretch-induced activation of transforming growth factor-beta1 in pulmonary fibrosis. *Am J Respir Crit Care Med*. 2016;194(1):84–96.
10. Finson KW, Almadani Y, Philip A. Non-canonical (non-SMAD2/3) TGF-beta signaling in fibrosis: mechanisms and targets. *Semin Cell Dev Biol*. 2020;101:115–22.
11. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. *Nat Rev Immunol*. 2004;4(8):583–94.
12. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. *Am J Respir Crit Care Med*. 2008;177(1):56–65.
13. Saito A, Horie M, Nagase T. TGF-beta signaling in lung health and disease. *Int J Mol Sci*. 2018;19(8):2460.
14. Jun JI, Lau LF. Resolution of organ fibrosis. *J Clin Investig*. 2018;128(1):97–107.

15. Horna-Terron E, Pradilla-Dieste A, Sanchez-de-Diego C, Osada J. TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology. *Int J Mol Sci.* 2014;15(12):23501–18.
16. Freedman RB, Hirst TR, Tuite MF. Protein disulphide isomerase: building bridges in protein folding. *Trends Biochem Sci.* 1994;19(8):331–6.
17. Alberti A, Karamessinis P, Peroulis M, Kypreou K, Kavvadas P, Pagakis S, et al. ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells. *Am J Physiol Endocrinol Metab.* 2009;297(3):E812–21.
18. Gu MX, Fu Y, Sun XL, Ding YZ, Li CH, Pang W, et al. Proteomic analysis of endothelial lipid rafts reveals a novel role of statins in antioxidant. *J Proteome Res.* 2012;11(4):2365–73.
19. Wang L, Dong H, Song G, Zhang R, Pan J, Han J. TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-kappaB signaling. *Cell Mol Immunol.* 2018;15(7):685–96.
20. Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulosom R, Creamer D, et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. *J Biol Chem.* 2003;278(47):47079–88.
21. Xu B, Li J, Wu C, Liu C, Yan X, Chang X. CXCL10 and TRAIL are upregulated by TXNDC5 in rheumatoid arthritis fibroblast-like synoviocytes. *J Rheumatol.* 2018;45(3):335–40.
22. Yeh CF, Cheng SH, Lin YS, Shentu TP, Huang RT, Zhu J, et al. Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo. *Sci Adv.* 2022;8(3): eab18096.
23. Wang L, Zheng Y, Xu H, Yan X, Chang X. Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. *PLoS ONE.* 2013;8(1): e53301.
24. Vincent EE, Elder DJ, Phillips L, Heesom KJ, Pawade J, Luckett M, et al. Overexpression of the TXNDC5 protein in non-small cell lung carcinoma. *Anticancer Res.* 2011;31(5):1577–82.
25. Shih YC, Chen CL, Zhang Y, Mellor RL, Kanter EM, Fang Y, et al. Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation. *Circ Res.* 2018;122(8):1052–68.
26. Lee TH, Yeh CF, Lee YT, Shih YC, Chen YT, Hung CT, et al. Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization. *Nat Commun.* 2020;11(1):4254.
27. Chen YT, Zhao PY, Hung CT, Wu YF, Lin SJ, Chiang WC, et al. Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts. *J Clin Investig.* 2021;131(5): e143645.
28. Hung CT, Su TH, Chen YT, Wu YF, Chen YT, Lin SJ, et al. Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling. *Gut.* 2021;71(9):1876–91.
29. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. *Eur Heart J.* 1998;19(Suppl P):P9–16.
30. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. *BMC Cancer.* 2010;10:105.
31. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. *N Engl J Med.* 2012;366(1):54–63.
32. Braunwald E. Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med.* 1997;337(19):1360–9.
33. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. *Circulation.* 1995;91(1):161–70.
34. Schwarz F, Mall G, Zebe H, Blicke J, Derks H, Manthey J, et al. Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. *Am J Cardiol.* 1983;51(3):501–6.
35. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, et al. Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. *Circ Cardiovasc Imaging.* 2009;2(6):437–43.
36. Karagueuzian HS. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? *Am J Cardiovasc Dis.* 2011;1(2):101–9.
37. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. *Pacing Clin Electrophysiol.* 1997;20(2 Pt 2):397–413.
38. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. *Heart Fail Rev.* 2004;9(1):53–61.
39. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. *Circulation.* 1995;91(10):2573–81.
40. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *J Am Coll Cardiol.* 2001;37(5):1228–33.
41. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). *Rales Investig Circ.* 2000;102(22):2700–6.
42. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. *Circulation.* 2002;106(1):130–5.
43. Lee KW, Everett TH, Rahmutula D, Guerra JM, Wilson E, Ding C, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. *Circulation.* 2006;114(16):1703–12.
44. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. *Cardiovasc Res.* 2005;65(3):694–701.
45. Holmes JS, Arispe IE, Moy E. Heart disease and prevention: race and age differences in heart disease prevention, treatment, and mortality. *Med Care.* 2005;43(3 Suppl):i33–41.
46. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. *Nat Med.* 2000;6(5):556–63.
47. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. *Lancet.* 2014;384(9949):1187–95.
48. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet.* 2004;364(9431):347–54.
49. Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. *Sci Transl Med.* 2015;7(277): 277ra31.
50. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. Micro-RNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature.* 2008;456(7224):980–4.
51. Xiong B, Jha V, Min JK, Cho J. Protein disulfide isomerase in cardiovascular disease. *Exp Mol Med.* 2020;52(3):390–9.
52. Zhou J, Wu Y, Wang L, Rauova L, Hayes VM, Poncz M, et al. The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis. *J Clin Investig.* 2015;125(12):4391–406.
53. Li J, Kim K, Jeong SY, Chiu J, Xiong B, Petukhov PA, et al. Platelet protein disulfide isomerase promotes glycoprotein Ibalph-mediated platelet-neutrophil interactions under thromboinflammatory conditions. *Circulation.* 2019;139(10):1300–19.
54. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. *Respir Res.* 2021;22(1):197.
55. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, et al. Idiopathic pulmonary fibrosis in Taiwan—a population-based study. *Respir Med.* 2012;106(11):1566–74.
56. Mora AL, Rojas M, Pardo A, Selman M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. *Nat Rev Drug Discov.* 2017;16(11):810.

57. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. *Proc Am Thorac Soc*. 2006;3(4):357–63.
58. Ruiz V, Ordonez RM, Berumen J, Ramirez R, Uhal B, Becerril C, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. *Am J Physiol Lung Cell Mol Physiol*. 2003;285(5):L1026–36.
59. Baek HA, Kim DS, Park HS, Jang KY, Kang MJ, Lee DG, et al. Involvement of endoplasmic reticulum stress in myofibroblastic differentiation of lung fibroblasts. *Am J Respir Cell Mol Biol*. 2012;46(6):731–9.
60. Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C, Chen YH, et al. Melatonin inhibits endoplasmic reticulum stress and epithelial–mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. *PLoS ONE*. 2014;9(5):e97266.
61. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research N. Prednisone, azathioprine, and *N*-acetylcysteine for pulmonary fibrosis. *N Engl J Med*. 2012;366(21):1968–77.
62. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev*. 2003;3:CD002880.
63. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *Am J Respir Crit Care Med*. 2008;178(9):948–55.
64. Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. *Eur Respir J*. 2015;46(6):1740–50.
65. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. *J Pharmacol Exp Ther*. 1999;291(1):367–73.
66. Schaefer CJ, Ruhmundt DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. *Eur Respir Rev*. 2011;20(120):85–97.
67. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glasspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370(22):2083–92.
68. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. *Eur Respir J*. 2010;35(4):821–9.
69. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet*. 2011;377(9779):1760–9.
70. Nathan SD, Albera C, Bradford WZ, Costabel U, Glasspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. *Lancet Respir Med*. 2017;5(1):33–41.
71. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370(22):2071–82.
72. Levey AS, Coresh J. Chronic kidney disease. *Lancet*. 2012;379(9811):165–80.
73. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. *Adv Exp Med Biol*. 2019;1165:3–15.
74. Tsai MH, Hsu CY, Lin MY, Yen MF, Chen HH, Chiu YH, et al. Incidence, prevalence, and duration of chronic kidney disease in taiwan: results from a community-based screening program of 106,094 individuals. *Nephron*. 2018;140(3):175–84.
75. Mezzano SA, Ruiz-Ortega M, Egidio J. Angiotensin II and renal fibrosis. *Hypertension*. 2001;38(3 Pt 2):635–8.
76. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. *J Clin Investig*. 1994;93(6):2431–7.
77. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. *Nephrol Dial Transplant*. 2006;21(1):16–20.
78. Sanz AB, Ramos AM, Soler MJ, Sanchez-Nino MD, Fernandez-Fernandez B, Perez-Gomez MV, et al. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. *Expert Rev Proteom*. 2019;16(1):77–92.
79. Koo JW. Renal interstitial fibrosis and angiotensin inhibition. *Electrolytes Blood Press*. 2006;4(1):35–43.
80. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. *J Am Soc Nephrol*. 2006;17(4):943–55.
81. Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L, et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. *Hypertension*. 2006;48(5):965–71.
82. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. *Hypertension*. 2001;37(2 Pt 2):490–6.
83. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. Avasentan for overt diabetic nephropathy. *J Am Soc Nephrol*. 2010;21(3):527–35.
84. Egidio J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz AB, Gonzalez Parra E, et al. Atrasentan for the treatment of diabetic nephropathy. *Expert Opin Investig Drugs*. 2017;26(6):741–50.
85. Klinkhammer BM, Goldschmeding R, Floege J, Boor P. Treatment of renal fibrosis—turning challenges into opportunities. *Adv Chronic Kidney Dis*. 2017;24(2):117–29.
86. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. *J Am Soc Nephrol*. 2005;16(9):2702–13.
87. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. *Am J Kidney Dis*. 2009;53(4):606–16.
88. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. *J Am Soc Nephrol*. 2004;15(6):1430–40.
89. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. *Clin J Am Soc Nephrol*. 2010;5(8):1420–8.
90. Arnott JA, Lambi AG, Mundy C, Hendsi H, Pixley RA, Owen TA, et al. The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. *Crit Rev Eukaryot Gene Expr*. 2011;21(1):43–69.
91. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, et al. Pirfenidone is renoprotective in diabetic kidney disease. *J Am Soc Nephrol*. 2009;20(8):1765–75.
92. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, et al. Pirfenidone for diabetic nephropathy. *J Am Soc Nephrol*. 2011;22(6):1144–51.
93. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol*. 2007;2(5):906–13.
94. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. *Liver Int*. 2018;38(Suppl 1):2–6.
95. Friedman SL. Liver fibrosis—from bench to bedside. *J Hepatol*. 2003;38(Suppl 1):S38–53.
96. Bataller R, Brenner DA. Liver fibrosis. *J Clin Investig*. 2005;115(2):209–18.
97. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. *N Engl J Med*. 2004;350(16):1646–54.
98. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. *J Gastroenterol Hepatol*. 2006;21(Suppl 3):S84–7.
99. Kalluri R, Neilson EG. Epithelial–mesenchymal transition and its implications for fibrosis. *J Clin Investig*. 2003;112(12):1776–84.
100. Gomperts BN, Strieter RM. Fibrocytes in lung disease. *J Leukoc Biol*. 2007;82(3):449–56.
101. Fallowfield JA, Mizuno M, Kendall TJ, Constantinou CM, Benyon RC, Duffield JS, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. *J Immunol*. 2007;178(8):5288–95.
102. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol*. 2017;14(7):397–411.
103. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev*. 2008;88(1):125–72.
104. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis*. 2001;21(3):311–35.
105. Senoo H, Kojima N, Sato M. Vitamin A-storing cells (stellate cells). *Vitam Horm*. 2007;75:131–59.



106. Mederacke I, Dapito DH, Affo S, Uchinami H, Schwabe RF. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. *Nat Protoc.* 2015;10(2):305–15.
107. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. *Compr Physiol.* 2013;3(4):1473–92.
108. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? *Antivir Res.* 2014;107:23–30.
109. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. *Aliment Pharmacol Ther.* 2012;35(6):674–89.
110. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinus A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. *Gastroenterology.* 2018;154(8):2111–2121.e8.
111. Khan A, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. *Clin Gastroenterol Hepatol.* 2016;14(2):191–202.e1–4 (quiz e20).
112. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2018;67(1):328–57.
113. Loomba R, Ratzliff V, Harrison SA, Group NCTDIW. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. *Gastroenterology.* 2022;162(3):680–8.
114. Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. *Gut.* 2020;69(10):1877–84.
115. Lafeber FP, Van der Laan WH. Progression of joint damage despite control of inflammation in rheumatoid arthritis: a role for cartilage damage driven synovial fibroblast activity. *Ann Rheum Dis.* 2012;71(6):793–5.
116. Li J, Xu B, Wu C, Yan X, Zhang L, Chang X. TXNDC5 contributes to rheumatoid arthritis by down-regulating IGFBP1 expression. *Clin Exp Immunol.* 2018;192(1):82–94.
117. Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. *Am J Respir Cell Mol Biol.* 2020;62(4):413–22.
118. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. *J Inher Metab Dis.* 1998;21(Suppl 1):101–11.
119. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43(4):333–8.
120. Kolb PS, Ayaub EA, Zhou W, Yum V, Dickhout JG, Ask K. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. *Int J Biochem Cell Biol.* 2015;61:45–52.
121. Park CS, Cha H, Kwon EJ, Sreenivasaiiah PK, Kim DH. The chemical chaperone 4-phenylbutyric acid attenuates pressure-overload cardiac hypertrophy by alleviating endoplasmic reticulum stress. *Biochem Biophys Res Commun.* 2012;421(3):578–84.
122. Ayala P, Montenegro J, Vivar R, Letelier A, Urroz PA, Copaja M, et al. Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. *Exp Mol Pathol.* 2012;92(1):97–104.
123. Chiang CK, Hsu SP, Wu CT, Huang JW, Cheng HT, Chang YW, et al. Endoplasmic reticulum stress implicated in the development of renal fibrosis. *Mol Med.* 2011;17(11–12):1295–305.
124. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. *Hepatology.* 2009;50(1):291–308.
125. Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. *Mol Neurobiol.* 2012;46(2):475–86.
126. Liu C, Cao Y, Yang X, Shan P, Liu H. Tauroursodeoxycholic acid suppresses endoplasmic reticulum stress in the chondrocytes of patients with osteoarthritis. *Int J Mol Med.* 2015;36(4):1081–7.
127. Cho JG, Lee JH, Hong SH, Lee HN, Kim CM, Kim SY, et al. Tauroursodeoxycholic acid, a bile acid, promotes blood vessel repair by recruiting vasculogenic progenitor cells. *Stem Cells.* 2015;33(3):792–805.
128. Zhou Q, Wang D, Xu J, Chi B. Effect of tauroursodeoxycholic acid and 4-phenylbutyric acid on metabolism of copper and zinc in type 1 diabetic mice model. *Biol Trace Elem Res.* 2016;170(2):348–56.
129. Omura T, Asari M, Yamamoto J, Oka K, Hoshina C, Maseda C, et al. Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. *Biochem Biophys Res Commun.* 2013;432(4):689–94.
130. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. *Glob Adv Health Med.* 2014;3(3):58–69.
131. Adams CJ, Kopp MC, Larburu N, Nowak PR, Ali MMU. Structure and molecular mechanism of ER stress signaling by the unfolded protein response signal activator IRE1. *Front Mol Biosci.* 2019;6:11.
132. Kaplan A, Gaschler MM, Dunn DE, Colligan R, Brown LM, Palmer AG 3rd, et al. Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective. *Proc Natl Acad Sci USA.* 2015;112(17):E2245–52.
133. Hoffstrom BG, Kaplan A, Letso R, Schmid RS, Turmel GJ, Lo DC, et al. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. *Nat Chem Biol.* 2010;6(12):900–6.
134. Novak P, Soukup T. Calsequestrin distribution, structure and function, its role in normal and pathological situations and the effect of thyroid hormones. *Physiol Res.* 2011;60(3):439–52.
135. Bergstrom JH, Berg KA, Rodriguez-Pineiro AM, Stecher B, Johansson ME, Hansson GC. AGR2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus. *PLoS ONE.* 2014;9(8): e104186.
136. Saw PE, Song EW. siRNA therapeutics: a clinical reality. *Sci China Life Sci.* 2020;63(4):485–500.
137. Hoy SM. Patisiran: first global approval. *Drugs.* 2018;78(15):1625–31.
138. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):22–31.
139. Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, et al. Nanoparticle delivery of CRISPR/Cas9 for genome editing. *Front Genet.* 2021;12: 673286.
140. Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. *Signal Transduct Target Ther.* 2020;5(1):101.
141. Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. *Nature.* 2016;539(7629):384–9.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

